5 July 2017 - Patients with certain forms of lung cancer or sarcoma have now gained access to two new treatment options on the NHS in England after Merck’s Keytruda and Eli Lilly’s Lartruvo were added to the Cancer Drugs Fund.

Keytruda (pembrolizumab) can be used to treat advanced lung cancer in people who have specific protein and genetic markers, potentially giving 1,400 extra patients access to the immunotherapy.

The drug was recently recommended by NICE for routine by the NHS as a second line option for some patients with lung cancer; this new guidance allows its use via the CDF for who have not yet received any treatment for the disease while extra data is collected.

Read Pharma Times article